DU-125530 + fluoxetine

DU-125530 + fluoxetine is an investigational combination therapy studied for the treatment of major depressive disorder. It combines fluoxetine, a selective serotonin reuptake inhibitor (SSRI) widely used as an antidepressant, with DU-125530, a potent and selective antagonist of the 5-hydroxytryptamine (serotonin) receptor 1A (5-HT1A). The rationale behind this combination is that while SSRIs like fluoxetine increase synaptic serotonin levels, they also activate presynaptic 5-HT1A autoreceptors which can dampen serotonergic neurotransmission and delay therapeutic effects. By antagonizing these receptors with DU-125530, it was hypothesized that the onset or magnitude of antidepressant action could be enhanced. However, clinical studies have shown that adding DU-125530 to fluoxetine does not accelerate or augment its antidepressant effects in patients with major depression[1][4][5]. Mechanistically, while preclinical data confirmed effective blockade of both pre-and post-synaptic 5‑HT1A receptors by DU‑125530 and augmentation of SSRI-induced increases in extracellular serotonin, clinical benefit was not observed.